| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta-glucans are polysaccharides found in the cell walls of certain fungi, bacteria, and plants. • Enhanced anti-tumor activity: Beta-glucans have been shown to stimulate the immune system, increasing the production of cytokines and activating natural killer cells, which can help to destroy cancer cells. • Improved survival rates: • Increased expression of tumor suppressor genes: • Inhibition of cancer cell proliferation: • Enhanced chemotherapy efficacy: • Reduced cancer recurrence: beta-glucans — Beta-glucans are structurally diverse glucose polymers, most commonly β-(1→3)/(1→6)-linked fungal or yeast polysaccharides and β-(1→3)/(1→4)-linked cereal polysaccharides, that function primarily as innate immune response modifiers rather than conventional directly cytotoxic small molecules. They are best classified as immunomodulatory polysaccharides / biological response modifiers, with common abbreviations including β-glucan, BG, and for specific products lentinan or LNT. Their biological activity is highly source-, branching-, solubility-, and particle-size-dependent, which is a major reason why “beta-glucans” should be treated as a family rather than a single interchangeable agent. In oncology, the strongest evidence base is for adjunctive use of selected fungal β-glucans, especially lentinan-based regimens in East Asian practice, rather than for broad standalone anticancer efficacy. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral beta-glucans are generally poorly digested and have limited measurable systemic absorption; clinical activity after oral dosing is thought to depend mainly on gut-associated immune signaling and downstream myeloid activation. Injectable purified fungal preparations such as lentinan bypass part of this delivery constraint and are more relevant to oncology translation. In-vitro vs systemic exposure relevance: Many direct tumor-cell effects reported in vitro use purified products and exposure conditions that are not easily mapped to achievable systemic concentrations after oral supplementation. For most oral products, the clinically relevant mechanism is not high free plasma exposure but immune-cell and mucosal engagement. Clinical evidence status: Adjunctive human evidence exists, strongest for selected purified fungal β-glucans such as lentinan combined with chemotherapy in gastric cancer, but the class as a whole remains heterogeneous and is not established as a standalone anticancer therapy. Overall evidence level: preclinical to small/moderate human adjunctive, with limited high-quality modern global RCT standardization. reference summaries describe about 2–10 mg IV lentinan weekly as the general adjunctive range used in Japan with chemotherapy.In general, bigger size and more complex β-glucans such as those derived from Ganoderma lucidum have higher immunomodulating potency. Lentinan(LNT) are macromolecules with a β-1,3-D-glucan and its unique molecular structure is closely related to its pharmacological activity, and the glucan of the β-glycosidic bond is the key structure for its antitumor function. Beta-glucans are not one thing. Cancer relevance depends more on source, linkage pattern, branching, solubility, and molecular weight/conformation than on the name alone. The table below is a practical comparison of the main beta-glucan families, with effectiveness interpreted as the strength of anticancer evidence, not a direct potency score.
Mechanistic matrix
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Plays a key role in activation of cellular immunity and subsequently, stimulation of antitumor immune-response. Based on its cytostatic, pro-apoptotic and antiproliferative functions, IFN-γ is considered potentially useful for adjuvant immunotherapy for different types of cancer. Moreover, it IFN-γ may inhibit angiogenesis in tumor tissue, induce regulatory T-cell apoptosis, and/or stimulate the activity of M1 proinflammatory macrophages to overcome tumor progression. However, the current understanding of the roles of IFN-γ in the tumor microenvironment (TME) may be misleading in terms of its clinical application. IFN-γ is often expressed in the tumor microenvironment, particularly in response to immune cell infiltration. Its expression can be influenced by the presence of tumor-infiltrating lymphocytes (TILs) and other immune cells. High levels of IFN-γ are typically associated with a Th1 immune response, which is generally considered beneficial for anti-tumor immunity. Tumor Suppression: In many cases, IFN-γ has tumor-suppressive effects, as it can inhibit tumor cell proliferation and induce apoptosis in certain cancer types. |
| 874- | B-Gluc, | Potential promising anticancer applications of β-glucans: a review |
| - | Review, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:245 Target#:442 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid